<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581476</url>
  </required_header>
  <id_info>
    <org_study_id>RP06</org_study_id>
    <secondary_id>2007-001039-72</secondary_id>
    <nct_id>NCT01581476</nct_id>
  </id_info>
  <brief_title>Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial</brief_title>
  <acronym>AdDIT</acronym>
  <official_title>Randomised, Double Blind, Placebo Controlled Trial of Angiotensin Converting Enzyme Inhibitors and Statins in the Prevention of Long Term Complications in Young People With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diabetes UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Western Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Thomas' Hospital, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether use of blood pressure lowering drugs,
      Angiotensin converting enzyme inhibitors (ACEIs) and blood fat (lipid) lowering drugs
      (statins) may have a place in the treatment of adolescents with diabetes and can help reduce
      serious long-term health problems in this population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be recruited from a pre-screened population of 3,000 young people with T1D aged
      10 to 16 years based on assessment of risk for future CVD and DN.

      They will be randomised to a 2 x 2 factorial design contrasting the effects of ACEI, statins,
      or combination therapy to placebo over a maximum four year treatment period. Minimisation of
      variation in albumin excretion rate, gender, age, diabetes duration, HbA1c, total cholesterol
      and centre site will be undertaken at randomisation.

      Analysis of the primary endpoint, change in albumin excretion will be undertaken on an
      intention to treat basis. Secondary analyses will be undertaken on the basis of 'as treated'
      allowing for variance in compliance and allowing for subjects who show substantial change in
      HbA1c levels. Additional analyses will be undertaken to assess changes in the secondary
      objectives and to assess the overall effect of the intervention on quality of life and health
      economics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Albumin creatinine ratio</measure>
    <time_frame>2-4 years treatment duration</time_frame>
    <description>The area under the curve over time of log ACR per year, with standardisation for gender, age and duration of disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in CVD risk markers</measure>
    <time_frame>2-4 yrs treatment duration</time_frame>
    <description>Changes in measures of:
cIMT, FMD, EndoPAT and PWV between baseline and the end of intervention period;
arterial BP, lipids and other lipoproteins, CVD risk markers (hsCRP and ADMA), assessed every 6 months during the intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glomerular filtration rate (GFR)</measure>
    <time_frame>2-4 years treatment duration</time_frame>
    <description>Changes in measures of GFR (plasma SDMA, creatinine adn cystatin C levels) assessed every 6 months during intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinopathy</measure>
    <time_frame>2-4 years treatment duration</time_frame>
    <description>Changes in retinopathy scores and retinal microvascular structure (arteriolar or venular dilation, vascular fractile dimension, branching and tortuosity) assessed annually</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Health Economics</measure>
    <time_frame>2-4 years treatment duration</time_frame>
    <description>Changes in quality of life measures and resource usage</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">443</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Statin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive active statin and placebo ACEI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACEI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive active ACEI and placebo statin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo ACEI and placebo statin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive both active ACEI and active Statin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <description>10mg daily for a minimum period of 2 years</description>
    <arm_group_label>Statin</arm_group_label>
    <other_name>Atorvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACEI</intervention_name>
    <description>Starting dose of 5mg daily rising after 14 days to 10mg daily providing it is well tolerated for a minimum period of 2 years.</description>
    <arm_group_label>ACEI</arm_group_label>
    <other_name>Quinapril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants receive statin placebo and ACEI placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination therapy</intervention_name>
    <description>Participants receive both active statin and active ACEI. Dose for Statins is 10mg daily. Dosing for ACEI starts at 5mg daily rising to 10mg after 14 days providing it is well tolerated. Both interventions last for a minimum of 2 years.</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>Atorvastatin</other_name>
    <other_name>Quinapril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 10 to 16 years.

          2. T1D diagnosed for more than 1 year or C-peptide negative.

          3. Centralised assessment of ACR based on six early morning urines deemed to be in upper
             tertile for risk after adjustment for age, gender, age at diagnosis and duration of
             disease.

        Exclusion Criteria:

          1. Non T1D, i.e. type 2 diabetes, insulin dependent diabetes related to monogenic
             disease, secondary diabetes.

          2. ACR based on six early morning urines deemed to be at low risk for subsequent
             development of CVD or DN.

          3. Pregnancy or unwillingness to comply with contraceptive advice and regular pregnancy
             testing throughout the trial.

          4. Breast feeding

          5. Severe hyperlipidaemia and family history data to support diagnosis of familial
             hypercholesterolaemia.

          6. Established hypertension unrelated to DN.

          7. Prior exposure to the investigational products, statins and ACEI.

          8. Unwillingness/inability to comply with the study protocol.

          9. Other co-morbidities considered unsuitable by the investigator (excluding treated
             hypothyroidism and coeliac disease).

         10. Proliferative retinopathy.

         11. Renal disease not associated with Type 1 Diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David B Dunger, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Western Australia</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.addit-trial.org</url>
    <description>Click here for information about the Adolescent Type 1 Diabetes Cardio Renal Intervention Trial (AdDIT)</description>
  </link>
  <reference>
    <citation>Amin R, Widmer B, Prevost AT, Schwarze P, Cooper J, Edge J, Marcovecchio L, Neil A, Dalton RN, Dunger DB. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ. 2008 Mar 29;336(7646):697-701. doi: 10.1136/bmj.39478.378241.BE. Epub 2008 Mar 18.</citation>
    <PMID>18349042</PMID>
  </reference>
  <reference>
    <citation>Dunger DB, Schwarze CP, Cooper JD, Widmer B, Neil HA, Shield J, Edge JA, Jones TW, Daneman D, Dalton RN. Can we identify adolescents at high risk for nephropathy before the development of microalbuminuria? Diabet Med. 2007 Feb;24(2):131-6.</citation>
    <PMID>17257274</PMID>
  </reference>
  <reference>
    <citation>Adolescent type 1 Diabetes cardio-renal Intervention Trial Research Group. Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT). BMC Pediatr. 2009 Dec 17;9:79. doi: 10.1186/1471-2431-9-79.</citation>
    <PMID>20017932</PMID>
  </reference>
  <results_reference>
    <citation>Cherney DZ, Scholey JW, Daneman D, Dunger DB, Dalton RN, Moineddin R, Mahmud FH, Dekker R, Elia Y, Sochett E, Reich HN. Urinary markers of renal inflammation in adolescents with Type 1 diabetes mellitus and normoalbuminuria. Diabet Med. 2012 Oct;29(10):1297-302. doi: 10.1111/j.1464-5491.2012.03651.x.</citation>
    <PMID>22416821</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cambridge</investigator_affiliation>
    <investigator_full_name>David Dunger</investigator_full_name>
    <investigator_title>Professor David Dunger</investigator_title>
  </responsible_party>
  <keyword>Adolescence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Quinapril</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

